Catalyst Wire Dossier Catalyst Wire Dossier

Frevecitinib (KN-002)

Frevecitinib · Kinaset Therapeutics Inc
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Frevecitinib (KN-002), covering 2026-04-20 to 2026-04-20. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma [Phase 2]

See pricing